American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Supernus Pharmaceuticals, Inc.

SUPN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

SUPN historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of SUPN by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar 03, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec 11, 2025
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Oct 09, 2025
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar 24, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec 23, 2022
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Nov 13, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jul 17, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jun 01, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 May 28, 2020
SUPN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
SUPN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SUPN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in SUPN holdings by institutional investors

Insider Trading

Quarterly net insider trading by SUPN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $20,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $20,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $20,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $50,000 Jan 20, 2026 Issue: Health Issues
  • $20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Sep 25, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Jul 18, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid
  • $20,000 Oct 17, 2024 Issue: Medicare/Medicaid Health Issues
  • $20,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Feb 07, 2023 Issue: Medicare/Medicaid Health Issues
  • $20,000 Oct 19, 2022 Issue: Medicare/Medicaid Health Issues
Revolving Door

Former government officials who have lobbied for SUPN

8 former government officials from 6 congressional offices at 2 lobbying firms have lobbied for SUPN, most recently Jul 20, 2026.

  • Marsha Blackburn
    Keith Studdard House Legislative Director, Rep. Marsha Blackburn Formerly with Marsha Blackburn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Lamar Alexander
    John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Mike Kelly
    John Ray House Legislative Assistant, Rep. Mike Kelly Formerly with Mike Kelly · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • John Cornyn
    Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services Formerly with John Cornyn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Lamar Alexander
    Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Cathy McMorris Rodgers
    Kristin Fritsch House Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce Formerly with Cathy McMorris Rodgers · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Kelsey Carlson Congress Special Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of Commerce Formerly Special Assistant, National Security Council; Special Assistant, International T · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Mar 12, 2026
  • J. Dennis Hastert
    Darren Willcox House New Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director Formerly with J. Dennis Hastert · W STRATEGIES, LLC · Apr 16, 2018
Corporate Lobbying

SUPN Estimated quarterly lobbying spending

Revenue Breakdown

SUPN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SUPN Income Statement
SUPN Balance Sheet
SUPN Cash Flow
U.S. Patents

New SUPN patent grants

  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jan. 02, 2018
  • Patent Title: Methods of producing molindone and its salts Oct. 31, 2017
  • Patent Title: Method of treatment of aggression Oct. 31, 2017
  • Patent Title: Topiramate compositions and methods of enhancing its bioavailability Aug. 29, 2017
  • Patent Title: Formulations of viloxazine May. 30, 2017
  • Patent Title: Sustained-release formulations of topiramate Apr. 18, 2017
  • Patent Title: Formulations of viloxazine Mar. 28, 2017
  • Patent Title: Osmotic drug delivery system Feb. 14, 2017
  • Patent Title: Methods of producing molindone and its salts Feb. 07, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 31, 2017
  • Patent Title: Sustained-release formulations of topiramate Jan. 24, 2017
  • Patent Title: Viloxazine compositions Sep. 06, 2016
  • Patent Title: Methods for producing viloxazine salts and novel polymorphs thereof Aug. 02, 2016
  • Patent Title: Osmotic drug delivery system Jul. 19, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jun. 21, 2016
  • Patent Title: Formulations of viloxazine Jun. 07, 2016
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof May. 31, 2016
  • Patent Title: Less abusable pharmaceutical preparations Apr. 12, 2016
  • Patent Title: Drug formulations having reduced abuse potential Sep. 29, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 01, 2015
  • Patent Title: Sustained-release formulations of topiramate Mar. 31, 2015
  • Patent Title: Methods of producing molindone and its salts Feb. 17, 2015
  • Patent Title: Drug formulations having reduced abuse potential Dec. 09, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 18, 2014
  • Patent Title: Sustained-release formulations of topiramate Nov. 04, 2014
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 02, 2014
  • Patent Title: Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics Aug. 19, 2014
  • Patent Title: Stabilized formulations of cns compounds Jun. 10, 2014
  • Patent Title: Osmotic drug delivery system Jun. 10, 2014
  • Patent Title: Once daily formulations of tetracyclines Apr. 29, 2014
  • Patent Title: Compositions of quaternary ammonium compounds containing bioavailability enhancers Apr. 29, 2014
  • Patent Title: Sustained-release formulations of topiramate Mar. 04, 2014
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Dec. 31, 2013
  • Patent Title: Controlled release compositions of gamma-hydroxybutyrate Dec. 03, 2013
  • Patent Title: Once daily formulations of tetracyclines Jun. 25, 2013
  • Patent Title: Once daily formulations of tetracyclines Mar. 12, 2013
  • Patent Title: Once daily formulations of tetracyclines Mar. 12, 2013
  • Patent Title: Sustained-release formulations of topiramate Oct. 30, 2012
  • Patent Title: Sustained-release formulations of topiramate Oct. 30, 2012
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Jul. 03, 2012
  • Patent Title: Once daily formulations of tetracyclines Jun. 26, 2012
  • Patent Title: Controlled release compositions of gamma-hydroxybutyrate Jun. 05, 2012
  • Patent Title: Modified release preparations containing oxcarbazepine and derivatives thereof Sep. 13, 2011
  • Patent Title: Method of treating seizures using modified release formulations of oxcarbazepine Mar. 22, 2011
  • Patent Title: Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics Mar. 22, 2011
  • Patent Title: Trospium chloride treatment method Aug. 24, 2010
  • Patent Title: Once daily dosage forms of trospium Aug. 24, 2010
  • Patent Title: Method of treating bladder dysfunction with once-a-day trospium salt formulation Jul. 20, 2010
  • Patent Title: Once daily formulations of tetracyclines Jul. 06, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to SUPN from public contracts

SUPN News

Recent insights relating to SUPN

CNBC Recommendations

Recent picks made for SUPN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SUPN

SUPN Analyst Ratings

SUPN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SUPN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SUPN stock a Buy, Sell, or Hold?

  • What is the price target for $SUPN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SUPN Top Shareholders
Shareholder
Shares Held
SUPN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SUPN stock?

  • Who owns the most shares of $SUPN stock?

  • What funds own $SUPN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SUPN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SUPN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About SUPN

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Address Rockville, MD
  • Market Cap 2.5 billion
  • Employees 778
  • Industrial Classification Pharmaceutical Preparations

Supernus Pharmaceuticals, Inc. (SUPN) Historical Stock Prices

Supernus Pharmaceuticals, Inc. (SUPN) closed at $43.39 on September 23, 2026. Over the past year its adjusted close ranged from $41.28 to $57.00. Daily prices go back to January 2, 2014, 3,200 trading days in all.

  • 1 month-3.81%
  • 3 months-3.88%
  • Year to date-12.70%
  • 1 year-7.35%
  • 3 years+54.03%
  • 5 years+56.02%
  • Max+467.19%
See every congressional and insider trade on the SUPN price chart

Quiver Premium charts SUPN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 43.66 44.46 43.14 43.39 43.39 544,530
Sep 22, 2026 43.04 44.25 42.82 43.75 43.75 667,587
Sep 21, 2026 42.00 42.97 41.68 42.78 42.78 635,721
Sep 18, 2026 42.89 42.89 41.60 42.00 42.00 1,182,919
Sep 17, 2026 41.66 43.40 41.46 42.92 42.92 559,774
Sep 16, 2026 41.31 41.84 40.75 41.38 41.38 787,815
Sep 15, 2026 41.49 41.75 40.51 41.28 41.28 669,223
Sep 14, 2026 42.16 42.54 41.23 41.49 41.49 678,060
Sep 11, 2026 41.81 42.44 41.62 41.64 41.64 707,159
Sep 10, 2026 41.84 42.55 41.11 41.69 41.69 726,749
Sep 9, 2026 42.17 42.59 41.50 42.07 42.07 580,434
Sep 8, 2026 43.56 43.56 42.32 42.43 42.43 429,133
Sep 4, 2026 43.66 44.11 43.43 43.53 43.53 444,197
Sep 3, 2026 44.56 44.56 43.16 43.97 43.97 390,320
Sep 2, 2026 44.42 45.05 43.67 44.03 44.03 445,942
Sep 1, 2026 44.35 44.75 43.53 43.74 43.74 757,781
Aug 31, 2026 43.82 44.37 42.84 44.21 44.21 535,722
Aug 28, 2026 43.95 44.34 43.12 43.73 43.73 487,925
Aug 27, 2026 44.87 45.03 43.89 44.19 44.19 464,947
Aug 26, 2026 45.11 45.43 44.50 44.88 44.88 499,684
Aug 25, 2026 45.37 45.85 44.23 45.36 45.36 496,056
Aug 24, 2026 45.60 45.86 44.81 45.11 45.11 495,505
Aug 21, 2026 47.71 47.81 45.79 45.85 45.85 748,894
Aug 20, 2026 47.86 48.26 46.93 47.45 47.45 646,851
Aug 19, 2026 49.50 49.82 48.51 48.54 48.54 797,223
Aug 18, 2026 48.80 49.57 48.54 49.03 49.03 592,240
Aug 17, 2026 47.66 48.66 47.66 48.27 48.27 536,730
Aug 14, 2026 46.70 48.39 46.57 48.27 48.27 331,731
Aug 13, 2026 47.74 48.18 46.87 47.15 47.15 667,871
Aug 12, 2026 47.15 47.92 46.26 47.87 47.87 667,316
Aug 11, 2026 47.01 48.60 46.77 46.88 46.88 669,685
Aug 10, 2026 47.11 47.72 46.47 47.07 47.07 762,174
Aug 7, 2026 47.00 47.88 46.43 47.64 47.64 702,627
Aug 6, 2026 47.82 48.40 46.55 46.76 46.76 1,344,878
Aug 5, 2026 42.95 47.89 42.91 46.91 46.91 1,671,843
Aug 4, 2026 46.23 46.58 42.62 43.25 43.25 3,705,542
Aug 3, 2026 50.45 52.50 44.17 46.00 46.00 4,518,516
Jul 31, 2026 45.19 45.67 44.35 44.63 44.63 573,626
Jul 30, 2026 46.30 46.77 45.50 45.61 45.61 468,740
Jul 29, 2026 47.60 47.99 46.08 46.57 46.57 522,131
Jul 28, 2026 47.78 48.45 46.77 47.73 47.73 538,195
Jul 27, 2026 46.56 48.08 45.84 46.98 46.98 523,013
Jul 24, 2026 47.02 47.46 46.03 46.20 46.20 521,935
Jul 23, 2026 46.41 47.53 46.07 47.19 47.19 463,337
Jul 22, 2026 47.87 48.12 46.79 46.94 46.94 430,060
Jul 21, 2026 47.00 48.02 46.39 47.87 47.87 450,290
Jul 20, 2026 48.09 48.79 47.30 47.42 47.42 618,820
Jul 17, 2026 48.15 49.06 47.90 48.04 48.04 439,397
Jul 16, 2026 47.53 48.30 47.23 48.21 48.21 593,351
Jul 15, 2026 46.81 47.74 46.20 47.73 47.73 500,546
Jul 14, 2026 46.89 47.57 46.09 46.66 46.66 824,025
Jul 13, 2026 48.09 48.24 46.91 47.35 47.35 685,279
Jul 10, 2026 48.80 48.80 47.39 48.46 48.46 1,126,231
Jul 9, 2026 50.82 51.37 47.88 48.75 48.75 1,296,246
Jul 8, 2026 47.85 50.62 47.55 50.44 50.44 1,430,876
Jul 7, 2026 47.74 48.34 47.04 47.94 47.94 1,017,845
Jul 6, 2026 47.62 48.12 46.76 47.24 47.24 882,211
Jul 2, 2026 47.49 48.11 46.97 48.05 48.05 969,033
Jul 1, 2026 46.98 47.62 45.99 47.41 47.41 902,155
Jun 30, 2026 46.64 47.08 46.00 46.51 46.51 1,146,256
Jun 29, 2026 46.49 46.85 45.80 46.80 46.80 974,438
Jun 26, 2026 44.75 47.13 44.75 46.84 46.84 3,338,838
Jun 25, 2026 44.94 45.46 44.49 44.75 44.75 697,624
Jun 24, 2026 44.55 45.50 44.12 45.14 45.14 759,697
Jun 23, 2026 44.69 45.50 44.44 44.48 44.48 544,634
Jun 22, 2026 44.50 45.00 44.09 44.48 44.48 513,750
Jun 18, 2026 44.07 44.58 43.54 44.38 44.38 1,096,029
Jun 17, 2026 43.37 44.01 42.50 43.58 43.58 563,031
Jun 16, 2026 44.09 44.26 42.45 43.58 43.58 720,139
Jun 15, 2026 44.36 44.44 42.74 43.86 43.86 902,284
Jun 12, 2026 45.71 45.71 44.16 44.41 44.41 825,356
Jun 11, 2026 45.06 45.89 44.41 45.55 45.55 478,366
Jun 10, 2026 45.44 46.58 44.98 45.09 45.09 380,057
Jun 9, 2026 44.86 45.79 44.70 45.66 45.66 380,769
Jun 8, 2026 44.94 45.59 44.34 44.48 44.48 431,264
Jun 5, 2026 45.05 45.73 44.60 44.75 44.75 574,092
Jun 4, 2026 44.66 45.72 44.43 44.70 44.70 460,501
Jun 3, 2026 43.93 44.98 43.45 44.03 44.03 1,003,055
Jun 2, 2026 44.25 44.47 43.45 44.07 44.07 711,350
Jun 1, 2026 45.83 46.16 44.17 44.76 44.76 571,040
May 29, 2026 46.60 47.15 45.96 46.18 46.18 544,813
May 28, 2026 46.63 47.76 45.92 46.85 46.85 635,593
May 27, 2026 47.76 48.38 46.40 46.64 46.64 710,985
May 26, 2026 48.44 48.68 47.42 47.77 47.77 474,838
May 22, 2026 49.38 49.83 48.17 48.21 48.21 526,838
May 21, 2026 48.68 49.66 47.98 49.38 49.38 529,463
May 20, 2026 48.27 49.24 47.67 48.69 48.69 606,181
May 19, 2026 48.38 48.53 47.52 47.62 47.62 591,522
May 18, 2026 49.34 50.00 47.85 48.33 48.33 568,937
May 15, 2026 50.88 50.88 49.15 49.43 49.43 616,053
May 14, 2026 51.73 52.35 50.58 51.20 51.20 558,690
May 13, 2026 50.02 51.50 50.02 51.36 51.36 432,254
May 12, 2026 49.61 50.58 48.84 50.53 50.53 589,558
May 11, 2026 51.04 51.74 49.13 49.37 49.37 853,179
May 8, 2026 52.46 52.59 50.35 51.53 51.53 854,620
May 7, 2026 51.45 52.50 49.78 52.28 52.28 1,055,334
May 6, 2026 50.67 52.96 46.87 51.45 51.45 1,922,563
May 5, 2026 49.07 50.55 48.10 49.19 49.19 1,121,313
May 4, 2026 47.53 49.01 47.34 48.63 48.63 1,391,912
May 1, 2026 48.02 48.33 47.17 47.85 47.85 622,225
Apr 30, 2026 48.75 49.24 47.85 48.00 48.00 855,492
Apr 29, 2026 48.42 48.90 47.62 48.55 48.55 512,541
Apr 28, 2026 50.06 50.13 48.12 48.69 48.69 697,054
Apr 27, 2026 49.58 50.18 49.17 49.46 49.46 709,656
Apr 24, 2026 50.39 50.51 48.71 49.76 49.76 482,160
Apr 23, 2026 50.75 51.43 49.45 50.39 50.39 301,634
Apr 22, 2026 49.42 50.31 49.01 50.29 50.29 391,683
Apr 21, 2026 51.06 51.13 48.98 49.12 49.12 502,294
Apr 20, 2026 51.10 51.37 50.50 51.25 51.25 426,535
Apr 17, 2026 49.78 52.31 49.61 51.39 51.39 797,784
Apr 16, 2026 49.83 49.89 48.35 49.22 49.22 494,499
Apr 15, 2026 50.11 50.91 49.48 49.94 49.94 349,023
Apr 14, 2026 50.63 51.03 49.76 50.11 50.11 460,025
Apr 13, 2026 50.64 50.80 49.65 49.95 49.95 347,444
Apr 10, 2026 51.62 51.71 50.00 50.68 50.68 445,337
Apr 9, 2026 51.43 52.32 51.00 51.50 51.50 498,756
Apr 8, 2026 51.97 52.37 50.71 51.61 51.61 618,498
Apr 7, 2026 50.20 51.06 49.56 50.96 50.96 873,941
Apr 6, 2026 50.23 51.24 49.82 50.54 50.54 438,419
Apr 2, 2026 50.49 51.37 50.08 50.48 50.48 472,496
Apr 1, 2026 51.37 52.69 51.32 51.44 51.44 624,450
Mar 31, 2026 49.81 51.94 49.65 51.69 51.69 396,201
Mar 30, 2026 49.88 50.07 48.85 49.35 49.35 560,681
Mar 27, 2026 50.36 51.13 49.00 49.52 49.52 547,753
Mar 26, 2026 50.37 51.00 49.22 50.80 50.80 387,771
Mar 25, 2026 50.01 50.78 49.81 50.06 50.06 438,153
Mar 24, 2026 48.80 49.87 48.23 49.38 49.38 660,873
Mar 23, 2026 48.86 49.36 47.75 49.25 49.25 831,311
Mar 20, 2026 49.09 49.29 46.83 47.76 47.76 1,279,868
Mar 19, 2026 49.07 49.87 48.56 48.84 48.84 569,112
Mar 18, 2026 50.48 50.48 48.91 49.29 49.29 575,962
Mar 17, 2026 50.13 51.15 49.40 50.82 50.82 549,292
Mar 16, 2026 50.01 51.00 47.71 50.21 50.21 518,505
Mar 13, 2026 50.76 51.81 49.64 49.91 49.91 802,078
Mar 12, 2026 51.80 52.20 50.42 50.46 50.46 534,869
Mar 11, 2026 53.16 53.41 51.38 53.22 53.22 555,009
Mar 10, 2026 54.29 56.00 53.61 53.67 53.67 514,467
Mar 9, 2026 53.56 54.30 52.27 54.17 54.17 801,842
Mar 6, 2026 53.43 54.24 52.27 53.87 53.87 649,634
Mar 5, 2026 54.81 55.34 52.50 54.27 54.27 880,214
Mar 4, 2026 54.72 56.49 54.16 55.58 55.58 615,979
Mar 3, 2026 54.27 55.00 52.95 54.56 54.56 720,184
Mar 2, 2026 53.99 55.28 53.30 55.09 55.09 474,117
Feb 27, 2026 56.59 56.59 53.11 54.73 54.73 875,702
Feb 26, 2026 55.60 56.38 54.05 55.75 55.75 1,249,201
Feb 25, 2026 56.50 59.68 55.34 56.32 56.32 2,820,352
Feb 24, 2026 50.95 53.68 50.77 53.30 53.30 2,208,522
Feb 23, 2026 50.75 51.23 49.63 50.69 50.69 563,504
Feb 20, 2026 51.48 51.88 50.19 50.86 50.86 758,571
Feb 19, 2026 50.27 51.62 49.60 51.35 51.35 773,991
Feb 18, 2026 51.65 51.65 50.02 50.20 50.20 494,613
Feb 17, 2026 50.87 51.97 50.46 51.62 51.62 720,980
Feb 13, 2026 49.85 51.41 49.46 50.84 50.84 738,653
Feb 12, 2026 51.37 51.59 49.76 49.85 49.85 675,941
Feb 11, 2026 51.17 51.61 49.94 51.34 51.34 656,694
Feb 10, 2026 51.44 51.93 50.64 51.18 51.18 495,044
Feb 9, 2026 51.75 51.96 50.36 51.30 51.30 654,421
Feb 6, 2026 50.01 51.99 50.01 51.65 51.65 893,956
Feb 5, 2026 48.98 50.10 48.92 49.37 49.37 565,508
Feb 4, 2026 48.42 49.47 48.20 49.08 49.08 665,344
Feb 3, 2026 48.86 49.70 47.29 48.40 48.40 773,467
Feb 2, 2026 48.15 49.49 48.11 48.78 48.78 1,011,502
Jan 30, 2026 48.73 49.07 48.02 48.16 48.16 792,911
Jan 29, 2026 48.74 49.35 48.03 49.06 49.06 826,812
Jan 28, 2026 49.41 50.09 48.41 48.94 48.94 788,888
Jan 27, 2026 49.11 49.53 48.73 49.44 49.44 478,209
Jan 26, 2026 48.07 49.67 48.07 49.16 49.16 815,412
Jan 23, 2026 48.81 49.04 47.94 48.25 48.25 699,894
Jan 22, 2026 49.68 50.45 48.98 49.10 49.10 782,440
Jan 21, 2026 49.65 50.25 48.84 49.52 49.52 506,394
Jan 20, 2026 49.72 50.55 48.88 49.82 49.82 935,170
Jan 16, 2026 50.19 50.42 49.52 50.00 50.00 581,504
Jan 15, 2026 51.78 52.34 50.08 50.26 50.26 653,443
Jan 14, 2026 51.23 52.20 50.61 51.80 51.80 701,295
Jan 13, 2026 51.07 51.57 49.41 51.45 51.45 698,490
Jan 12, 2026 52.17 52.50 50.65 51.36 51.36 712,771
Jan 9, 2026 52.00 52.38 50.45 51.11 51.11 1,220,251
Jan 8, 2026 51.32 51.83 50.45 51.17 51.17 352,816
Jan 7, 2026 50.15 51.41 49.90 51.24 51.24 587,339
Jan 6, 2026 49.18 49.53 47.80 49.26 49.26 650,018
Jan 5, 2026 49.25 49.77 48.27 49.40 49.40 448,597
Jan 2, 2026 49.70 50.05 48.37 49.47 49.47 374,859
Dec 31, 2025 50.00 50.10 49.32 49.70 49.70 364,279
Dec 30, 2025 51.32 51.41 49.69 49.89 49.89 367,670
Dec 29, 2025 51.55 51.75 51.14 51.25 51.25 385,115
Dec 26, 2025 51.77 52.02 51.29 51.57 51.57 366,371
Dec 24, 2025 52.21 52.30 51.01 51.77 51.77 209,018
Dec 23, 2025 51.47 52.28 51.25 51.71 51.71 1,323,520
Dec 22, 2025 51.37 51.66 50.60 51.50 51.50 471,677
Dec 19, 2025 48.90 52.11 47.98 51.48 51.48 1,620,487
Dec 18, 2025 48.87 49.78 48.63 49.28 49.28 722,178
Dec 17, 2025 48.46 49.40 48.18 48.75 48.75 495,544
Dec 16, 2025 47.28 48.84 47.20 48.32 48.32 619,210
Dec 15, 2025 47.23 47.80 46.76 47.28 47.28 687,671
Dec 12, 2025 46.96 47.57 46.36 47.16 47.16 611,775
Dec 11, 2025 46.42 47.34 45.88 46.51 46.51 451,801
Dec 10, 2025 45.62 46.90 45.43 46.16 46.16 663,519
Dec 9, 2025 47.01 47.24 45.36 45.42 45.42 584,062
Dec 8, 2025 46.32 47.26 45.75 47.16 47.16 919,252
Dec 5, 2025 44.94 45.88 44.51 45.68 45.68 458,559
Dec 4, 2025 44.76 45.10 44.28 45.10 45.10 493,658
Dec 3, 2025 44.27 45.06 44.21 44.76 44.76 527,464
Dec 2, 2025 44.70 44.90 44.09 44.12 44.12 624,380
Dec 1, 2025 45.38 45.58 44.65 44.70 44.70 565,144
Nov 28, 2025 46.39 46.56 45.53 45.59 45.59 433,428
Nov 26, 2025 46.14 47.00 45.72 46.26 46.26 989,396
Nov 25, 2025 45.62 46.79 45.16 46.08 46.08 993,962
Nov 24, 2025 45.50 46.00 45.00 45.15 45.15 821,282
Nov 21, 2025 44.73 46.09 44.37 45.32 45.32 636,479
Nov 20, 2025 46.23 46.47 44.76 44.79 44.79 744,337
Nov 19, 2025 44.69 46.00 44.52 45.70 45.70 541,813
Nov 18, 2025 45.11 45.73 44.05 44.90 44.90 810,558
Nov 17, 2025 45.30 45.96 44.70 45.09 45.09 700,123
Nov 14, 2025 44.48 45.58 44.22 45.00 45.00 724,910
Nov 13, 2025 44.61 45.70 44.23 44.44 44.44 1,143,051
Nov 12, 2025 46.06 46.26 44.12 44.62 44.62 1,401,994
Nov 11, 2025 45.40 46.59 44.47 46.11 46.11 1,026,458
Nov 10, 2025 46.08 46.53 44.51 45.40 45.40 1,094,155
Nov 7, 2025 46.77 47.48 45.82 46.02 46.02 928,005
Nov 6, 2025 47.08 47.69 45.63 47.27 47.27 1,441,745
Nov 5, 2025 44.70 51.52 43.11 47.11 47.11 3,999,312
Nov 4, 2025 55.43 57.40 54.61 57.00 57.00 1,478,961
Nov 3, 2025 55.28 56.17 54.27 55.70 55.70 1,090,944
Oct 31, 2025 56.33 57.33 54.21 55.13 55.13 904,189
Oct 30, 2025 55.61 57.65 55.02 56.50 56.50 859,196
Oct 29, 2025 54.90 55.95 53.16 55.68 55.68 2,314,768
Oct 28, 2025 52.72 53.38 51.84 53.17 53.17 410,434
Oct 27, 2025 54.00 54.78 52.61 52.72 52.72 507,584
Oct 24, 2025 52.30 53.28 52.30 52.83 52.83 840,147
Oct 23, 2025 51.07 53.04 50.70 52.02 52.02 891,616
Oct 22, 2025 50.72 51.47 49.95 50.67 50.67 561,904
Oct 21, 2025 51.43 51.60 50.33 50.67 50.67 422,142
Oct 20, 2025 50.44 52.15 50.10 51.59 51.59 741,230
Oct 17, 2025 49.69 50.85 49.44 50.17 50.17 630,165
Oct 16, 2025 49.22 49.77 48.97 49.76 49.76 374,877
Oct 15, 2025 49.16 49.67 48.81 49.27 49.27 565,363
Oct 14, 2025 48.31 49.48 47.98 49.22 49.22 656,198
Oct 13, 2025 49.19 49.35 48.19 48.38 48.38 561,138
Oct 10, 2025 49.39 49.81 48.27 49.00 49.00 1,047,266
Oct 9, 2025 51.08 51.78 49.35 49.51 49.51 2,131,210
Oct 8, 2025 48.04 48.24 47.27 48.00 48.00 584,456
Oct 7, 2025 48.32 48.48 47.59 48.07 48.07 564,144
Oct 6, 2025 48.35 48.84 47.34 48.31 48.31 728,053
Oct 3, 2025 47.97 49.66 47.97 48.35 48.35 939,438
Oct 2, 2025 47.93 48.64 47.41 47.96 47.96 592,627
Oct 1, 2025 47.62 48.27 47.29 48.04 48.04 470,082
Sep 30, 2025 48.01 48.44 47.38 47.79 47.79 497,513
Sep 29, 2025 47.18 48.15 46.77 47.60 47.60 705,333
Sep 26, 2025 47.44 48.00 46.86 47.03 47.03 594,768
Sep 25, 2025 46.97 47.52 46.31 47.18 47.18 726,113
Sep 24, 2025 46.88 47.17 46.44 47.10 47.10 459,628
Sep 23, 2025 46.70 47.65 46.42 46.83 46.83 736,536

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Supernus Pharmaceuticals, Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at SUPN, per a recent SEC DEF 14A filing. We estimate that the median employee at SUPERNUS PHARMACEUTICALS, INC. is paid $166,121.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation